Clinical trial · Observational
Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss
Role of Caspase-3, Phosphatidylinositol-3 Kinase (PI3K), and 3-methylhistidine (3-MH) in the Pathophysiology of Skeletal Muscle Loss in Weight-losing Pancreas Cancer Patients
NCT00899158CI-TRIAL-00019277completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Learning about biological markers in patients with pancreatic cancer and cachexia may help doctors predict patient outcome and may help the study of cancer in the future. PURPOSE: This laboratory study is examining biological markers in patients with pancreatic cancer experiencing weight loss.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy | Procedure | — | UNRESOLVED |
| immunologic technique | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (6)
- measure
- Skeletal muscle loss
- timeFrame
- Up to 6 months
- measure
- Lean body mass
- timeFrame
- Up to 6 months
- measure
- Time to progression
- timeFrame
- Up to 6 months
- measure
- Caspase-3 levels
- timeFrame
- Up to 6 months
- measure
- Phosphorylated Akt levels
- timeFrame
- Up to 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Meets 1 of the following criteria:
* Diagnosis or suspicion of pancreatic cancer
* Any stage disease allowed
* At least 5% weight loss within the past 6 months
* Scheduled to undergo exploratory surgery
* Scheduled to undergo exploratory surgery for suspected nonmalignant condition
* No weight loss OR weight loss due to specific reason (e.g., bowel obstruction, infection, or nausea/vomiting)
* No cancer diagnosis other than primary pancreatic carcinoma
PATIENT CHARACTERISTICS:
* ECOG performance status 0-3
* Life expectancy ≥ 12 weeks
* No pacemakers or implanted defibrillators
PRIOR CONCURRENT THERAPY:
* Prior or concurrent chemotherapy and radiotherapy allowed
* Prior or concurrent biological therapy and surgery allowed
* At least 4 weeks since prior corticosteroids or anabolic steroids
* Other concurrent anticancer therapy allowed
* No concurrent corticosteroids or anabolic steroids, thalidomide, eicosapentaenoic acid (EPA), or Juven for weight loss
* Concurrent steroids (i.e., antiemetics) associated with chemotherapy allowed
* No concurrent nutritional supplements with EPAReferences
Publications (0)
Data not yet available
No reference posted for this study.